
Gilead’s Seladelpar Gets Positive CHMP Opinion for Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) recently announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for the approval of seladelpar in treating primary biliary cholangitis (PBC). This treatment, which can…











